Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart in Refractory Chronic Inflammatory Demyelinating Polyneuropathy
NCT06290128Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- IgG Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Riliprubart Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of participants experiencing a response at 24 weeks, Percentage of participants randomized to riliprubart with lasting response at 48 weeks and 1 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06290128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290128.